Pure Global
NCT02290522

Copenhagen Prospective Personalized Oncology (CoPPO)

A Prospective Study Using Genomic Screening to Select Patients for Targeted Molecular Treatment
Ulrik Lassen·ClinicalTrials.gov·procedureRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
Tumor biopsy
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Ulrik Lassen
Funder
Rigshospitalet, Denmark
Location
Copenhagen, Denmark
Timeline & enrollment
Phase
N/A
Start date
May 01, 2013
End date
Dec 01, 2023
Enrollment
500 participants
Primary outcome

Median progression free survival (PFS)

Summary

Patients with advanced solid tumors referred to the Phase 1 Unit are offered mapping of GA
 for identification of pts who could benefit from a personalized treatment.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02290522
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02290522 through Pure Global AI's free database. This phase not specified trial is sponsored by Ulrik Lassen and is currently Recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.